Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupDHGR 59 EV-to-OCF is -1.87 as of Sep. 17, 2026. GuruFocus rates DHGR with a GF Score™ of 59/100 and a GF Value™ of $2.06 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,406 Biotechnology companies, Devonian Health Group ranks worse than 58.32% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Devonian Health Group's Enterprise Value is $15.92 Mil.
Devonian Health Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 was $-8.53 Mil. Therefore, Devonian Health Group's EV-to-OCF for today is -1.87.
The historical rank and industry rank for Devonian Health Group's EV-to-OCF or its related term are showing as below:
DHGR'
s EV-to-OCF Range Over the Past 10 Years
Min: -182.89 Med: -10.17 Max: 3.91
Current: -1.87
During the past 9 years, the highest EV-to-OCF of Devonian Health Group was 3.91. The lowest was -182.89. And the median was -10.17.
DHGR's EV-to-OCF is ranked worse than 58.32% of 1406
companies
in the Biotechnology industry
Industry Median: -3.335
vs DHGR: -1.87
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Devonian Health Group (AMEX:DHGR) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Devonian Health Group's PE Ratio (TTM) for today is calculated as:
Devonian Health Group's share price for today is $5.875.
Devonian Health Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.612.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Devonian Health Group's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's EV-to-OCF falls into.
Devonian Health Group's current Enterprise Value is $15.92 Mil.
Devonian Health Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group (DHGR) has a EV-to-OCF of -1.87 as of Sep. 17, 2026. According to the industry distribution chart, Devonian Health Group ranks #820 out of 1406 companies in the Biotechnology industry, placing it in the top 58.3%.
Is Devonian Health Group's EV-to-OCF too high?
Devonian Health Group's current EV-to-OCF is -1.87. Based on the distribution chart, Devonian Health Group ranks #820 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Devonian Health Group has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #820 out of 1406 companies for EV-to-OCF. This places Devonian Health Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Devonian Health Group's current EV-to-OCF is -1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DHGR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.06, compared to a current price of $5.88 — trading 185.2% above its estimated fair value. The current EV-to-OCF is -1.87. Devonian Health Group's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Devonian Health Group (DHGR), the current EV-to-OCF is -1.87 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DHGR) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $5.88 is trading 185.2% above its estimated GF Value™ of $2.06.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DHGR:
EV-to-OCF: -1.87
GF Value™: $2.06 vs. price of $5.88 (185.2% above fair value)
No single metric tells the full story. See the DHGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
59GF Score
Get the complete analysis for DHGR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHGR has been successfully added to your 
